A research advocate diagnosed with Parkinson’s disease and a former nurse with Alzheimer’s disease were among recipients of volunteer awards from the Global Alzheimer’s Platform Foundation (GAP). GAP’s Citizen Scientist Awards acknowledge the contributions of volunteers in clinical trials for neurodegenerative diseases. Each year, GAP’s network of research…
Moving Day, a signature fundraiser for the Parkinson’s Foundation, will join communities this spring to raise awareness and money to support care for people with Parkinson’s disease, and advance research toward better treatments. The events will take place in 33 cities across the U.S. from March 15 to…
Six months of treatment with intranasal FGF-1, a naturally occurring molecule that promotes blood vessel growth, improved blood flow in a brain region profoundly affected by Parkinson’s disease, along with motor function, in the first patient to undergo both assessments. That’s according to a press release by…
Sexual health among women with Parkinson’s disease is associated with sleep quality and the quality of the relationships they have with their partners, a study in Brazil found. The study analyzed the short- and long-term sexual health of 100 women with mild to moderate disease who were sexually active…
Estrogen, a female sex hormone, was found to enhance the neuroprotective effects of cytisine, a smoking cessation drug, in a female mouse model of Parkinson’s disease. That’s according to a study conducted by researchers at Texas A&M University, which analyzed the effects of cytisine in female mice that had…
A grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will allow Australia-based Kazia Therapeutics to explore the potential of paxalisib — an investigational anticancer drug now being tested in clinical trials — as a repurposed treatment for Parkinson’s disease. The research grant will fund…
Subsense has received $17 million in seed funding to accelerate the development of a nanoparticle-based brain-computer interface to help monitor and treat people with neurological conditions, including Parkinson’s disease. The funding will help the company develop nanoparticles for precise stimulation and monitoring of brain activity, along with hardware…
Researchers in the U.K. have successfully generated small antibodies, or nanobodies, that can target toxic aggregates of misfolded proteins, including alpha-synuclein, a hallmark of Parkinson’s disease. The antibodies, which were generated using a new antibody-discovery platform, can help understand how protein clumps, or aggregates are formed, and identify specific…
Swedish-based Smartcella has entered an agreement with a research team from the Karolinska Institute for the exclusive rights to advance a cell replacement therapy for Parkinson’s disease into clinical development and commercialization. The Karolinska Institute team in Sweden, led by Johan Ericson, PhD, a professor of developmental biology, has…
Kenai Therapeutics is setting up research and laboratory facilities at Lilly Gateway Labs in San Diego, to help advance RNDP-001, its investigational dopaminergic neuron replacement therapy for Parkinson’s disease. By joining Gateway Labs, Kenai, formerly Ryne Biotechnologies, will have access to state-of-the-art facilities, along with resources and…
Get regular updates to your inbox.
